AID Genomics

Executive Summary

AID Genomics is an Israeli R&D-driven diagnostics company specializing in next-generation sequencing (NGS), miRNA, and epigenetic-based tests integrated with AI analytics. Its focus spans early cancer detection, therapy selection, hereditary rare diseases, and infectious diseases. Founded in 2018 and headquartered in Rehovot, Israel, the company has raised $20 million to date. With a commercial-stage status and a team of 50-200 employees, AID Genomics leverages multi-omics approaches to develop non-invasive liquid biopsy and blood-based assays. The company's AI platform enhances sensitivity and specificity, aiming to improve patient outcomes through earlier diagnosis and personalized treatment guidance. Its positioning in Israel’s vibrant biotech ecosystem provides access to top-tier research talent and collaborative opportunities. As AID Genomics advances its pipeline, key milestones include potential regulatory filings and clinical validations. The company's tests address high unmet needs in oncology and rare diseases, where timely diagnosis is critical. With growing demand for precision medicine and AI-driven diagnostics, AID Genomics is well-placed to capture market share. The $20 million raised signals investor confidence, and additional funding rounds may fuel expansion and commercialization. Ongoing partnerships with healthcare institutions could accelerate adoption. While specific financial details remain private, the company’s proprietary technology and commercial focus suggest a path to revenue growth and possible strategic exits.

Upcoming Catalysts (preview)

• Q1 2027FDA 510(k) clearance for hereditary rare disease NGS panel65% success
• Q4 2026Publication of clinical validation data for AI-driven early cancer detection test70% success
• Q2 2027Strategic partnership with a pharma company for companion diagnostics55% success